Patient Files: haemophilia
Jess Page details her experiences living with a bleeding disorder
PharmaTimes Magazine
PharmaTimes is the UK's leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.
PharmaTimes print and digital magazine has a distributed circulation of 19,000, reaching right across the industry into every company and every function, bridging the gap between Pharma and the NHS.
Click to subscribe to PharmaTimes in paper or print, or to sign up for our industry-leading daily and weekly news elerts.
You can read the latest issue as well as our extensive archive below or get in touch with the editorial or sales team.
Digital edition sponsored by
Magazine highlights
View more from the latest edition
Non-traditional pharma trademarks: colours
Should pharma companies consider protecting colours that are key to their products?
MAGAZINE EXCLUSIVE
AE reporting turnarounds present a multilingual challenge
Kathleen O’Brien looks at how to bring worldwide adverse event (AE) reporting under control – and why it matters
MAGAZINE EXCLUSIVE
Why predictive modelling and machine learning can revolutionise the biopharma industry
This new direction has been influenced by the convergence of several trends
Lone, remote workers and business travellers
Are employers doing enough to fulfil their duty of care to an overlooked workforce?
Parallel pandemics
Extracting value from the lessons of COVID-19 to empower people living with HIV
Clinical research outsourcing: prioritising safety
Using third parties for clinical research support services has numerous practical advantages, but if pharma companies unwittingly cut corners on safety oversight, they could be risking more than they realise – including multiplying their costs. Natalia Vlcek offers some practical tips for covering all bases when partnering externally
Meeting the post-pandemic needs of rare disease patients
What actions can the pharma industry take that will have a direct impact on the rare disease community?
